Trastuzumab deruxtecan is a costly ADC that delivers chemo directly to HER2-low cells, which is why it works, but its "bystander effect" can damage nearby lung tissue. As a health economist, I must note that our public scheme simply cannot afford such precision drugs for every HER2-low case, even if they are breakthroughs. I’ve seen tankers ration water in our colony—it’s the same brutal math of allocating a limited resource. So the real issue isn't just the lung problems, yaar, it's whether we fund this or buy ten thousand cheaper mammograms instead.
#exams#study
Jump in to reply — no account needed.